NCT00166517

V260 Registration Study (V260-013)(COMPLETED)

Immunogenicity and Safety of V260 in Healthy Infants in Korea

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 178 (actual)
• Sponsor: Merck Sharp & Dohme LLC · Industry
• Sex: All
• Age: 6 Weeks – 12 Weeks
• Healthy volunteers: Accepted

Summary

Immunogenicity and Safety of V260 in Healthy Infants in Korea

Conditions

• Rotavirus

Interventions

Type	Name	Description
BIOLOGICAL	Rotavirus Vaccine, Live, Oral, Pentavalent	3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
BIOLOGICAL	Comparator: Placebo	3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2

Timeline

• Start date: 2005-08-01
• Primary completion: 2006-07-01
• Completion: 2006-07-01
• First posted: 2005-09-14
• Last updated: 2015-04-01
• Results posted: 2009-09-23